Avidity Biosciences Inc
RNAM
株式のランク
#2068
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
株価
$71.34
最終同期: 2026-03-03
時価総額
$9.84B
変化（1日）
0.00%
変化（1年）
-
国
US
取引 Avidity Biosciences Inc (RNAM)
カテゴリー
Healthcare
Avidity Biosciences Inc（RNAM）の発行済株式数
October 2026 時点の発行済株式数 0
Avidity Biosciences Inc の最新の財務報告および株価によると、現在の発行済株式数は 0 です。October 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Avidity Biosciences Inc（RNAM）の発行済株式数の履歴（2018 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2025 | 137.71M | 23.42% |
| 2024 | 111.58M | 52.83% |
| 2023 | 73.01M | 39.97% |
| 2022 | 52.16M | 25.91% |
| 2021 | 41.43M | 91.24% |
| 2020 | 21.66M | -42.27% |
| 2019 | 37.53M | 0.04% |
| 2018 | 37.51M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 0.00 | - |
BE
|
|
| 62.19M | - |
NL
|
